Efficacy and safety of dextromethorphan/quinidine in prophylactic treatment of migraine in patients with multiple sclerosis with superimposed pseudobulbar affect

Trial Profile

Efficacy and safety of dextromethorphan/quinidine in prophylactic treatment of migraine in patients with multiple sclerosis with superimposed pseudobulbar affect

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 New trial record
    • 22 Feb 2018 Results published in the Clinical Neuropharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top